Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Holding PSIL?
Track your performance easily
PSIL Price & Analysis
PSIL ETF Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $2.24
Previous Close$1.23
VolumeN/A
Average Volume (3M)74.76K
AUM6.77M
NAV1.22
Expense Ratio0.99%
Holdings Count24
Beta0.77
Inception DateSep 15, 2021
Last Dividend Ex-Date
Sep 25, 2023Dividend Yield
<0.01 (―)Shares Outstanding3,510,000
Standard Deviation0.13
10 Day Avg. Volume54,116
30 Day Avg. Volume74,763
Alpha-0.06
AdvisorShares Psychedelics ETF (PSIL) Fund Flow Chart
AdvisorShares Psychedelics ETF (PSIL) 1 year Net Flows: $3M
PSIL ETF News
PremiumCompany Announcements
NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal
PremiumCompany Announcements
GH Research Plc Schedules AGM for Shareholder Voting
PremiumCompany Announcements
ATAI Life Sciences Announces CEO Transition and Compensation TermsPSIL ETF FAQ
What was PSIL’s price range in the past 12 months?
PSIL lowest ETF price was $1.20 and its highest was $2.24 in the past 12 months.
What is the AUM of PSIL?
As of May 15, 2024 The AUM of PSIL is 6.77M.
Is PSIL overvalued?
According to Wall Street analysts PSIL’s price is currently Undervalued.
Does PSIL pay dividends?
PSIL pays a Annually dividend of <$0.01 which represents an annual dividend yield of N/A. See more information on PSIL dividends here
How many shares outstanding does PSIL have?
PSIL has 3,510,000 shares outstanding.
Which hedge fund is a major shareholder of PSIL?
Currently, no hedge funds are holding shares in PSIL
Top 10 Holdings
Mind Medicine Inc.
15.86%
Cybin, Inc.
9.19%
Compass Pathways Plc
7.10%
Gh Research Plc
6.13%
Atai Life Sciences N.V.
5.97%
Nrx Pharmaceuticals, Inc.
5.87%
Vistagen Therapeutics Inc.
5.29%
Intra-Cellular Therapies
4.84%
Alkermes plc
4.64%
Psyence Biomedical Ltd.
4.03%
Total68.92%
ETF Description
AdvisorShares Psychedelics ETF
PSIL is actively managed to provide exposure to the emerging global psychedelics industry.